Explore active and passive temperature-controlled shipping solutions and their impact on clinical trial supply, balancing cost, risk, and product integrity.
- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To Commercialization
While in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.
-
Development And Characterization Of The Species-Specific Liver-Chip
There is a growing need for more human-relevant preclinical models. Explore how Organ-Chips offer a viable solution and can be used to create a comprehensive recapitulation of the liver sinusoid.
-
Support The Culture Of Adherent Vero Cells With A Serum-Free Medium
This study compares a serum-free medium to other commercially available pre-hydrated media to measure it's effectiveness in supporting the culture of adherent Vero cells.
-
Advances In Flow-Through Technology To Enhance mAb Polishing
Optimize your monoclonal antibody purification with cutting-edge flow-through chromatography. Learn how POROS resins enhance polishing efficiency, improve aggregate removal, and streamline bioprocessing.
-
Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy
Hereditary transthyretin amyloidosis (ATTRv) is very rare, prompting a Phase 1 trial of in vivo CRISPR/Cas9 gene editing to reduce mutant protein and stop cardiomyopathy progression.
-
Mixing Of Various Dry Powdered Media And Buffers
Explore how this mixing system efficiently handles various powdered media and buffers, ensuring precise solubilization and mixing in applications like cell culture and protein purification.
-
Pave The Way To High Productivity With Continuous Manufacturing For Pharma
Continuous manufacturing delivers agility and precision for pharma, combining automation, reduced manual steps, and quality control to meet regulatory and cost pressures while accelerating development.
-
The Key To Viral Vector Success
Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.
-
Development Of LNP Formulations Using The KNAUER NanoScaler
Lipid nanoparticles (LNPs) offer a robust solution for nucleic acids. The NanoScaler system optimizes this technology, enabling scalable and reproducible LNP formulations for diverse applications.
-
Monitoring Bioprocesses In A Light Environment Using Raman Spectroscopy
Discover an advanced solution to facilitate the implementation of Raman technology at both laboratory and manufacturing scales in a normal light environment.
NEWSLETTER ARCHIVE
- 02.17.26 -- STREAM Edition: Introducing mRNA Hot Takes, A New Video Series From Advancing RNA
- 02.17.26 -- Leveraging Conventional Therapeutics Skills For Cell And Gene Therapy
- 02.16.26 -- Derisk Multimodal CGT Manufacturing With These Key CDMO Capabilities
- 02.14.26 -- Cell & Gene Best Of January
- 02.13.26 -- Strengthening Your Regulatory Path: Strategies For Compliance And Safety
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections